Literature DB >> 7961637

Ligand-independent anti-oncogenic activity of the alpha subunit of the type I interferon receptor.

O R Colamonici1, B Porterfield, P Domanski, R K Handa, S Flex, C E Samuel, R Pine, M O Diaz.   

Abstract

Two interferon (IFN) alpha-regulated genes, IRF1/ISGF2 and PKR/p68 kinase, may function as tumor suppressor genes suggesting that the IFN system may function as a tumor suppressor system. We report that the expression of the alpha subunit of the type I IFN receptor in human K-562 cells had anti-oncogenic effects that include a marked decrease in: (i) cell proliferation rate, (ii) the cell density at which growth arrest normally occurs, and (iii) the tumorigenicity in nude mice. Furthermore, expression of the alpha subunit in K-562 cells induced erythroid differentiation. While most cytokine receptors become activated after binding their corresponding ligands, the overexpression of the alpha subunit has a physiological effect in the absence of its natural ligand, type I IFNs, suggesting a novel function for this type I IFN receptor subunit. The anti-oncogenic effect of the alpha subunit is mediated by a pathway that does not involve two tumor suppressor genes induced by type I IFNs, the transcriptional regulator IFN response factor-1 and the RNA-dependent protein kinase, or the p135tyk2 tyrosine kinase that directly associates and phosphorylates the alpha subunit.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961637

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Ligand-independent pathway that controls stability of interferon alpha receptor.

Authors:  Jianghuai Liu; Alexander Plotnikov; Anamika Banerjee; K G Suresh Kumar; Josiane Ragimbeau; Zrinka Marijanovic; Darren P Baker; Sandra Pellegrini; Serge Y Fuchs
Journal:  Biochem Biophys Res Commun       Date:  2007-12-31       Impact factor: 3.575

2.  Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells.

Authors:  S Arab; M Murakami; P Dirks; B Boyd; S L Hubbard; C A Lingwood; J T Rutka
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

3.  Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells.

Authors:  K G Suresh Kumar; Jianghuai Liu; Ying Li; Duonan Yu; Andrei Thomas-Tikhonenko; Meenhard Herlyn; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2007-06-13       Impact factor: 4.742

4.  Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC.

Authors:  Susana Guerra; José Luis Nájera; José Manuel González; Luis A López-Fernández; Nuria Climent; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

5.  SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor.

Authors:  K G Suresh Kumar; Weigang Tang; Abhilash K Ravindranath; William A Clark; Ed Croze; Serge Y Fuchs
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

Review 6.  Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.

Authors:  Serge Y Fuchs
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

7.  Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.

Authors:  Francesco Sabbatino; Yangyang Wang; Giosuè Scognamiglio; Elvira Favoino; Steven A Feldman; Vincenzo Villani; Keith T Flaherty; Sjoerd Nota; Diana Giannarelli; Ester Simeone; Anna M Anniciello; Giuseppe Palmieri; Stefano Pepe; Gerardo Botti; Paolo A Ascierto; Cristina R Ferrone; Soldano Ferrone
Journal:  J Natl Cancer Inst       Date:  2016-02-05       Impact factor: 11.816

8.  A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.

Authors:  Ester Simeone; Giosuè Scognamiglio; Mariaelena Capone; Diana Giannarelli; Antonio M Grimaldi; Domenico Mallardo; Gabriele Madonna; Marcello Curvietto; Assunta Esposito; Fabio Sandomenico; Francesco Sabbatino; Nicholas L Bayless; Sarah Warren; SuFey Ong; Gerardo Botti; Keith T Flaherty; Soldano Ferrone; Paolo A Ascierto
Journal:  J Transl Med       Date:  2021-01-06       Impact factor: 8.440

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.